Esposito et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;(18):198–209.

Mincham K. et al. Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation. J Clin Invest. 2018. doi: 10.1172/JCI122631..
DOI: 10.1172/JCI122631

Dang A.T. et al. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Scientific Reports. 2017;(7):1–9.

Parola C. et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PloS one. 2013;8(12).

Pasquali C. et al. Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract. Frontiers in medicine. 2014;(1):41.

Jara-Pérez J.V., Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clinical therapeutics. 2000;22(6):748–759.

Selwyn B. on behalf of the coordinated data group of Bostid researchers. Comparisons among countries: the epidemiology of acute respiratory infections in young children: comparison of findings from several developing countries. Rev Infect Dis. 1990;12(8):870–888.

Cohen A.J. et al. The global burden of disease due to outdoor air pollution. Journal of Toxicology and Environmental Health, Part A. 2005;68(13–14):1301–1307.

Gutiérrez-Tarango M.D., Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119(6):1742–1748.

Gomez Barreto D., De la Torre C., Alvarez A. et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergologia et immunopatho­ logia. 1998;26(1):17–22.

Esposito S. et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32(22):2546–2552.

Esposito S. et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. Journal of translational medicine. 2019;17(1):284.

Esposito S. et al. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. International journal of envi­ ronmental research and public health. 2019;16(6):1065.

Razi C.H. et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. Journal of allergy and clinical immunol­ ogy. 2010;126(4):763–769.

Han R.F. et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci. 2016;20(10):2151–2155.